Back to Product News Main Page

New Overactive Bladder Treatment Does Not Impair Cognition

A new study published in The Journal of Urology reports that Enablex^®, a once-daily treatment for overactive bladder (OAB), does not impair cognition in elderly patients. Older individuals- in this study people over age 65- make up the majority of OAB sufferers, as the prevalence of the condition increases significantly with age. Older people are also more susceptible to cognitive disorders as well as drug-induced cognitive impairment.

This study evaluated the effects of Enablex on cognitive function in 129 volunteers aged 65 or older without clinical dementia. While the study was powered to detect an improvement in cognitive function, the authors noted that Enablex had no effect on the three primary cognitive endpoints: memory scanning sensitivity, speed of choice reaction time, and word recognition sensitivity, at any dose. The most common treatment-related adverse events were dry mouth and constipation, which were typically of mild or moderate intensity.

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis.

back to top